VivoSim Labs Inc. Common Stock (VIVS)
Stock · NASDAQ · Health Care
$0.1553as of 10/16/2026
Price chart
Active signals
VIVS Signal Track Record
How signals performed across all stocks →What VIVS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 26 | -15.3% | 23% | September 10, 2026 |
| Bollinger Band Breakdown | 22 | +0.1% | 50% | September 16, 2026 |
| Bollinger Band Breakout | 19 | -8.8% | 21% | January 30, 2026 |
| 200-Day Moving Average TouchActive now | 6 | -10.4% | 0% | February 26, 2026 |
| Any 20-session window (baseline) | -8.2% | 30% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About VIVS
VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models. The company also provides liver toxicology predictive screening and research services, as well as works on predicting…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 15
- Website
- organovo.com/
Fundamentals
- 1-day range
- $0.1528$0.169
- Market cap
- $5.53M
- P/E (trailing)
- —
- P/E (forward)
- —
- EPS (trailing)
- $-4.45
- Dividend yield
- —
- Beta
- 1.57
- Avg. volume
- 3.94M
- Dividend pay date
- August 19, 2020
How VivoSim Labs Inc. Common Stock Makes Money
Where the revenue actually goes — FY2026 annual results
Source: 10-K filed Jul 14, 2026 · via SEC EDGAR / Finnhub
VivoSim Labs Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- VIVSVivoSim Labs Inc. Common Stock$0.16▼ 5.88%Market cap $5.53MP/E —$0.1495$3.4
- BCABBioAtla Inc. Common Stock$1.36▲ 4.62%Market cap $5.53MP/E —$1.07$71.5
- PMCBPharmaCyte Biotech Inc. Common Stock$0.3402▼ 4.81%Market cap $6.34MP/E —$0.3339$1.51
- LIMNLiminatus Pharma Inc. Class A Common Stock$3.04▼ 5.30%Market cap $6.64MP/E —$3.25$141.5
- CLDICalidi Biotherapeutics Inc. Common Stock$0.837▼ 3.79%Market cap $4.38MP/E —$0.82$27.84
- AIMAIM ImmunoTech Inc. Common Stock$0.17▲ 0.00%Market cap $7.51MP/E —$0.1605$2.79
- CELZCreative Medical Technology Holdings Inc. Common Stock$0.741▼ 9.39%Market cap $7.58MP/E —$0.62$6.25
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| VIVS VivoSim Labs Inc. Common Stock | $5.53M | — | $0.16 | ▼ 5.88% | $0.1495$3.4 |
| BCAB BioAtla Inc. Common Stock | $5.53M | — | $1.36 | ▲ 4.62% | $1.07$71.5 |
| PMCB PharmaCyte Biotech Inc. Common Stock | $6.34M | — | $0.3402 | ▼ 4.81% | $0.3339$1.51 |
| LIMN Liminatus Pharma Inc. Class A Common Stock | $6.64M | — | $3.04 | ▼ 5.30% | $3.25$141.5 |
| CLDI Calidi Biotherapeutics Inc. Common Stock | $4.38M | — | $0.837 | ▼ 3.79% | $0.82$27.84 |
| AIM AIM ImmunoTech Inc. Common Stock | $7.51M | — | $0.17 | ▲ 0.00% | $0.1605$2.79 |
| CELZ Creative Medical Technology Holdings Inc. Common Stock | $7.58M | — | $0.741 | ▼ 9.39% | $0.62$6.25 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Vivosim Labs Notes FDA's Direct Final Rule Clarifying That Non-Animal Methods Can Be Used Where Appropriate For Testing Safety Of Drugs And Biological Products For Human Usebenzinga · 10/7/2026
- VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing MethodsYahoo · 10/7/2026
- Vivosim Labs Notes FDA's Direct Final Rule Clarifying That Non-Animal Methods Can Be Used Where Appropriate For Testing Safety Of Drugs And Biological Products For Human UseBenzinga · 10/7/2026
- VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCsYahoo · 9/16/2026
Insider Activity
Insider Actions →- Lialin Tony Serge · August 31, 2026 · Buy10.0K @ $0.2804
Institutional Ownership
March 31, 2026
- Total shares held
- 90.9K
- Total value held
- $130.0K
- Institutional holders
- 23
- Unknown36.9K
- Unknown16.1K
- Unknown15.4K
- Unknown11.8K
- Unknown6.5K
- Unknown2.3K
- Unknown952
- Unknown221
- Unknown208
- Unknown166
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Vivosim Labs Highlights FDA Rule Supporting Non‑Animal Drug Testing
Vivosim Labs announced that the FDA has issued a direct final rule allowing non‑animal methods for safety testing of drugs and biologics. The guidance confirms that the company’s non‑animal testing platform can be used in regulatory submissions. This regulatory clarification could broaden the market for Vivosim’s products and reduce the need for animal testing in drug development.
Vivosim Labs Highlights FDA Rule Supporting Non‑Animal Drug Testing. Vivosim Labs announced that the FDA has issued a direct final rule allowing non‑animal methods for safety testing of drugs and biologics. The guidance confirms that the company’s non‑animal testing platform can be used in regulatory submissions. This regulatory clarification could broaden the market for Vivosim’s products and reduce the need for animal testing in drug development.